Click Here to Register »

2018 Executive Sponsors

Adaptive Biotechnologies
Imaging Endpoints

2018 Supporting Partners

Trout Group

2018 Educational Partners

CIMT
CRI
SITC

2018 Media Partners

CanBiotech
Pharmalicensing
PharmaVOICE

2017 Executive Sponsors

Bioclinica
Imaging Endpoints
Mitra Biotech
nanoString Technologies
NeoGenomics
US Oncology Research

2017 Associate Sponsors

Adaptive Biotechnologies
Beigene
BioLegend
Cytel
Defined health
Immodulon Therapeutics
inVentiv Health
MacroGenics
Miltenyi Biotec
Neon Therapeutics
Parexel
Vector Vitale

2017 Exhibitors

Abcam
Axio Research
Caprion
Intrinsic Imaging
KIYATEC Inc
Personalis
QuickStat
World Courier

2017 Media Partners

BioPharm Insight
BioPharma Dive
CanBiotech
Clinical Leader
Life Science Leader
MNT
Pharmaceutical Online
Pharmalicensing
Pharmaphorum
PharmaVOICE
SciDoc Publishers
Technology Networks

The Premier Meeting Across all Stakeholders in Immuno-Oncology

2018 Featured Speakers

Overview

The Immuno-Oncology 360° summit gives attendees exposure to the entire spectrum of science — from discovery to translational and clinical, as well as, emerging technologies, business aspects, investor relations and trends in the field.

Designed by lead advisors Dr Axel Hoos, GSK and Dr James Gulley, NCI, Immuno-Oncology 360° provides the most up-to-date research, data and progress to help IO stakeholders:

  • Be at the forefront of the most relevant research and developments from key leadership who are at the pulse of cancer immunotherapy
  • Foster collaboration amongst others working in all aspects of cancer immunotherapy by rounding up all stakeholders under one roof​
  • Better understand what assets are available for potential combinations that may be able to give patients more treatment options
  • Create and prioritize strategies targeted toward specific tumor types​

TJ Sharpe

Melanoma Survivor T.J. Sharpe shared his journey in an immunotherapy trial at IO360° 2017

Dr Daniel Chen, Genentech, delivered a talk on cancer immunity cycle at IO360° 2017

Dr Patricia Keegan, FDA, discussed Modified RECIST 1.1 at IO360° 2017

Trends & Collaborations Panel at IO360° 2017
From Left to Right: Dr Ramy Ibrahim, Parker Research Institute for Cancer Immunotherapy, Dr David Wholley, Foundation for the National Institutes of Health, Dr Jill O’Donnell-Tormey, Cancer Research Institute, Dr Daniel Chen, Genentech

 

Sincerely,

kate-bw-3

Kate Woda
Conference Director

Valerie Bowling New

Valerie Bowling
Executive Director

meredith-sands-bw-new

Meredith Sands
Executive Director, Business Development

onaleesmith-bw

Onalee Smith
Marketing Manager

elizabeth-bard-bw-2

Elizabeth Bard
Business Development Manager

geeta-new-bw

Geeta Bachani
Business Development Manager

bridget_new_bw2

Bridget Murphy
Senior Conference Planner